EMJ Nephrology最新文献_第8页

More Frequent Haemodialysis Improved Outcomes: The Wish Comes True at Home 更频繁的血液透析改善了结果:在家里愿望成真

EMJ Nephrology Pub Date : 2017-07-18 DOI: 10.33590/emjnephrol/10312867

Blair R. Hesp

引用次数: 0

Vitamin D After Kidney Transplantation: Metabolism and Clinical Importance 肾移植后维生素D的代谢及其临床意义

EMJ Nephrology Pub Date : 2017-07-01 DOI: 10.33590/emjnephrol/10311600

J. Filipov, E. Dimitrov

引用次数: 2

Ophthalmology Cystinosis Forum Morning Session 眼科胱氨酸病论坛上午会议

EMJ Nephrology Pub Date : 2017-02-14 DOI: 10.33590/emjnephrol/10312504

Lynda M. McEvoy

{"title":"Ophthalmology Cystinosis Forum Morning Session","authors":"Lynda M. McEvoy","doi":"10.33590/emjnephrol/10312504","DOIUrl":"https://doi.org/10.33590/emjnephrol/10312504","url":null,"abstract":"This 1-day meeting was held at the Austria Trend Savoyen Hotel, Vienna, Austria. The morning session consisted of a series of presentations by experts in the field of cystinosis. Prof Katharina Hohenfellner gave an overview of nephropathic cystinosis (NC) and provided her own experience of a multidisciplinary patient follow-up. Dr Alexey Tsygin provided his long-term experience of treatment with cysteamine and highlighted the importance of treating early and the role of cysteamine in treating and preventing long-term complications of cystinosis. Dr Roser Torra presented the findings of the T-CiS.bcn project, which aimed to develop a transition plan from paediatric to adult care through a multidisciplinary team. Dr Rachel Bishop provided an overview of the ocular manifestations of cystinosis followed by a presentation on the most recent data with gel-like Cystadrops® from Dr Hong Liang.\u0000\u0000The key themes from the morning sessions were:\u0000\u0000With the development of specific treatment for cystinosis, the disease paradigm has shifted from a paediatric illness where patients suffer end-stage renal disease (ESRD) by 10 years of age to a longerterm multisystemic illness with extra-renal complications\u0000Earlier treatment of NC with cysteamine can delay both the renal and extra-renal manifestations of the disease\u0000There are difficulties in transitioning from paediatric to adult care and this can lead to reduced treatment adherence; a multidisciplinary team may help to smooth the transition","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"142 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122178356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ophthalmology Cystinosis Forum Afternoon Session 眼科胱氨酸病论坛下午会议

EMJ Nephrology Pub Date : 2017-02-14 DOI: 10.33590/emjnephrol/10312816

Lynda M. McEvoy

引用次数: 0

Fractional Excretion of Survivin, Extracellular Matrix Metalloproteinase Inducer, and Matrix Metalloproteinase 7 in Children with Chronic Kidney Disease 慢性肾病患儿存活素、细胞外基质金属蛋白酶诱导剂和基质金属蛋白酶7的部分排泄

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10311462

Agnieszka Bargenda, K. Musiał, D. Zwolińska

{"title":"Fractional Excretion of Survivin, Extracellular Matrix Metalloproteinase Inducer, and Matrix Metalloproteinase 7 in Children with Chronic Kidney Disease","authors":"Agnieszka Bargenda, K. Musiał, D. Zwolińska","doi":"10.33590/emjnephrol/10311462","DOIUrl":"https://doi.org/10.33590/emjnephrol/10311462","url":null,"abstract":"Background: Epithelial–mesenchymal transition (EMT) is defined as a transformation of tubular epithelial cells into mesenchymal ones. These cells migrate through the extracellular matrix and change into active myofibroblasts, which are responsible for excessive matrix deposition. Such changes may lead to tubular dysfunction and fibrosis of the renal parenchyma, characteristic of chronic kidney disease (CKD). However, there are no data on potential EMT markers in children with CKD. The aim of our study was to assess the usefulness of fractional excretion (FE) of survivin, E-cadherin, extracellular matrix metalloproteinase inducer (EMMPRIN), matrix metalloproteinase (MMP)7, and transforming growth factor beta 1 (TGF-β1) as potential markers of CKD-related complications such as tubular damage and fibrosis.\u0000\u0000Methods: Forty-one pre-dialysis children with CKD Stages 3–5 and 23 age-matched controls were enrolled in the study. The serum and urine concentrations of analysed parameters were assessed by an enzyme-linked immunosorbent assay test.\u0000\u0000Results: Tubular reabsorption of all analysed parameters was >99% in the control group. All FE values rose significantly in children with CKD, yet they remained <1% in the case of E-cadherin and TGF-β1. The highest FE values in CKD children were those of survivin, EMMPRIN, and MMP7: >1%.\u0000\u0000Conclusions: FE of the examined markers may become a useful tool in the assessment of tubular dysfunction during the course of CKD. The FE of survivin, EMMPRIN, and MMP7 warrant further research as potential independent markers of kidney-specific EMT.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125061067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality 转移性肾细胞癌透析患者的靶向药物:神话与现实

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10312156

A. Guida, L. Cosmai, F. Gelsomino, C. Masini, R. Sabbatini, C. Porta

{"title":"Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality","authors":"A. Guida, L. Cosmai, F. Gelsomino, C. Masini, R. Sabbatini, C. Porta","doi":"10.33590/emjnephrol/10312156","DOIUrl":"https://doi.org/10.33590/emjnephrol/10312156","url":null,"abstract":"Agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway, as well as mammalian target of rapamycin (mTOR) inhibitors have revolutionised the therapeutic landscape of metastatic renal cell carcinoma (mRCC) in the past decade, greatly improving the survival rates of these patients. However, translating results of registrative Phase III trials into everyday clinical practice is often troublesome, since real-world patients are completely different from those enrolled in randomised controlled Phase III trials. Prospective data on active oncological treatments in mRCC patients on dialysis are dramatically lacking. This literature review summarises and critically comments on available data relative to mRCC patients on dialysis receiving either VEGF/VEGFR-targeting agents, or mTOR inhibitors. Although prospective studies would definitely be warranted in these specific patient populations, all the available data suggest that mRCC patients on dialysis have the same outcome, both in terms of efficacy and safety, as mRCC patients with normal or marginally impaired kidney function, when treated with VEGF/VEGFR-targeting agents and/or mTOR inhibitors.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126368161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protecting Heart, Vessels, and Bone: New Ways to Control Phosphorus 保护心脏、血管和骨骼:控制磷的新方法

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10311623

Kabira Alieva

引用次数: 0

Secondary Carnitine Deficiency in Dialysis Patients: Shall We Supplement It? 透析患者继发性肉碱缺乏症:需要补充吗?

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10311145

J. Phillipson

{"title":"Secondary Carnitine Deficiency in Dialysis Patients: Shall We Supplement It?","authors":"J. Phillipson","doi":"10.33590/emjnephrol/10311145","DOIUrl":"https://doi.org/10.33590/emjnephrol/10311145","url":null,"abstract":"Carnitine, essential for fatty acid β-oxidation, is obtained from diet and through de novo biosynthesis. The organic cation/carnitine transporter 2 (OCTN2) facilitates carnitine cellular transport and kidney resorption. Carnitine depletion occurs in OCTN2-deficient patients, with serious clinical complications including cardiomyopathy, myopathy, and hypoketotic hypoglycaemia. Neonatal screening can detect OCTN2 deficiency. OCTN2-deficiency is also known as primary carnitine deficiency. Carnitine deficiency may result from fatty acid β-oxidation disorders, which are diagnosed via plasma acylcarnitine profiling, but also under other conditions including haemodialysis.\u0000\u0000Given the importance of the kidney in maintaining carnitine homeostasis, it is not unexpected that longterm haemodialysis treatment is associated with the development of secondary carnitine deficiency, characterised by low endogenous L-carnitine levels and accumulation of deleterious medium and long- chain acylcarnitines. These alterations in carnitine pool composition have been implicated in a number of dialysis-related disorders, including erythropoietin-resistant renal anaemia. The association between erythropoietin resistance and carnitine levels has been demonstrated, with the proportion of medium and long-chain acylcarnitines within the total plasma carnitine pool positively correlated with erythropoietin resistance. Recent research has demonstrated that carnitine supplementation results in a significant reduction in erythropoietin dose requirements in patients with erythropoietin-resistant anaemia.\u0000\u0000Few studies have been conducted assessing the treatment of carnitine deficiency and haemodialysisrelated cardiac complications, particularly in children. Thus, a study was recently conducted which showed that intravenous carnitine in children receiving haemodialysis significantly increased plasma carnitine.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129801921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Treating the Diabetic Hypertensive: Consensus and Differences 治疗糖尿病高血压:共识与差异

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10314843

A. Rahman

{"title":"Treating the Diabetic Hypertensive: Consensus and Differences","authors":"A. Rahman","doi":"10.33590/emjnephrol/10314843","DOIUrl":"https://doi.org/10.33590/emjnephrol/10314843","url":null,"abstract":"Hypertension and diabetes commonly coexist. Both are major modifiable risk factors for cardiovascular diseases. There has been a substantial shift in the recommendations of several expert committees on the management of hypertension in diabetics. It was once unanimously agreed by almost all major guidelines that the threshold for initiating diabetic patients with antihypertensive therapy is when blood pressure is >130/80 mmHg. The blood pressure target for treatment was also unanimously agreed to be <130/80 mmHg. These recommendations were, however, based on expert opinions and not on findings from major randomised controlled trials.\u0000\u0000Since then, there have been several randomised controlled trials looking at blood pressure-lowering in the diabetic population. These include the ADVANCE and ACCORD, and a subanalysis of the INVEST trials. Together with the earlier UKPDS and HOT trials, one would expect there to be more agreement in the most recent recommendations, but in fact the opposite is the case. There are now two different systolic targets (<130 mmHg and <140 mmHg) and three different diastolic targets (<90 mmHg, 85 mmHg, and <80 mmHg). The reason for this involves the choice of trials included in the recommendation, and the interpretation of results from these trials by various guideline committees.\u0000\u0000The recommendation for diabetic hypertensives will be more consistent if future trials begin by asking a relevant research question that has not yet been answered: does treating diabetics with different thresholds of blood pressure levels impact on clinical outcomes? The trial must not only determine a primary research question, but it must also be adequately powered to answer it. Only when this question is answered should the next questions be asked. Does it matter how blood pressure is lowered? And are some drugs better than others? In the meantime, guideline committees should try to narrow the gap in recommendations, particularly if the guidelines originate from the same country or region.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123747388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Insights into Iron Metabolism and Deficiency 对铁代谢和铁缺乏的新认识

EMJ Nephrology Pub Date : 2016-07-05 DOI: 10.33590/emjnephrol/10312295

T. Mughal

引用次数: 0